Seaport Therapeutics, Inc. (SPTX)
Health Care · Nasdaq
Clinical-stage biopharmaceutical company developing novel therapeutic candidates for serious disorders through advanced drug discovery platforms.
What Seaport Therapeutics, Inc. does
Seaport Therapeutics is a biopharmaceutical company focused on discovering and developing novel therapeutic candidates for serious disorders. The company leverages its platform technologies to identify and advance product candidates through preclinical studies and clinical trials, with a strategy to rapidly progress programs across target indications and expand its pipeline.
Themes: ["Drug discovery and development","Clinical trials","Therapeutic platform","Biopharmaceutical development","Clinical trial execution risk — successful completion and positive outcomes of current and future clinical trials are not guaranteed and may not demonstrate safety and efficacy of product candidates","Regulatory and manufacturing risk — ability to meet regulatory standards, obtain approvals, and manufacture product candidates at scale depends on third-party partners and evolving regulatory requirements","Financing and cash runway risk — company's ability to fund continued research, development, and clinical trials depends on securing additional capital and managing cash burn","Biopharmaceutical drug discovery and development"]
Fundamentals
- Price$21.58 as of 2026-07-10 close
- Market cap$1.2B as of 2026-07-12
- 1-year return+8.8% as of 2026-07-10 close
- ROE-24.2% as of 2026-07-12
- Debt / equity0.00 as of 2026-07-12
- Beta-2.19 as of 2026-07-12
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.